{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-046015","form_type":"8-K","ticker":"ROIV","cik":"0001635088","company_name":"Roivant Sciences Ltd.","filed_at":"2024-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.052596+00:00","generated_at":"2026-05-30T01:58:20.089674+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Roivant Q2 loss $236.8M; Dermavant deal closed; cash $5.4B; brepocitinib NIU data","bullets":["Q2 loss from continuing ops $236.8M ($0.25 EPS); R&D $143.1M; G&A $202.9M up $114.3M YoY on retention awards.","Dermavant transaction closed Oct 28: Roivant received $184M cash; Organon assumed $336M debt; $75M milestone pending VTAMA FDA approval for atopic dermatitis.","Consolidated cash, cash equivalents and marketable securities ~$5.4B at Sep 30, 2024.","Share repurchases $106M in Q2; cumulative $754M (incl. Sumitomo stake buyback).","Pipeline: brepocitinib Phase 2 NIU 52-wk data shows sustained efficacy; batoclimab GD 76% response; mosliciguat PVR reduction ~38%."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-046015","json":"https://secwatch.observer/filing/0001140361-24-046015.json","markdown":"https://secwatch.observer/filing/0001140361-24-046015.md","text":"https://secwatch.observer/filing/0001140361-24-046015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1635088/000114036124046015/0001140361-24-046015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1635088/000114036124046015/ef20038392_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T01:58:20.089674+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}